An open-label extension, multi-center, study to evaluate the safety of SD-101 cream in subjects with epidermolysis bullosa
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2018
At a glance
- Drugs Allantoin (Primary)
- Indications Epidermolysis bullosa
- Focus Adverse reactions
- Sponsors Amicus Therapeutics; Scioderm
- 12 Nov 2018 Status changed from active, no longer recruiting to discontinued.
- 10 Apr 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2018.
- 10 Apr 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2018.